Aclaris Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2012 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Aclaris Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2012 to Q4 2023.
  • Aclaris Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $195M, a 5.65% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $195M +$10.4M +5.65% Dec 31, 2023 10-K 2024-02-27
Q4 2022 $185M +$22.9M +14.1% Dec 31, 2022 10-K 2024-02-27
Q4 2021 $162M +$27.3M +20.3% Dec 31, 2021 10-K 2024-02-27
Q4 2020 $135M +$13.6M +11.2% Dec 31, 2020 10-K 2024-02-27
Q4 2019 $121M +$40M +49.4% Dec 31, 2019 10-K 2023-02-23
Q4 2018 $81M +$34.1M +72.8% Dec 31, 2018 10-K 2022-02-24
Q4 2017 $46.9M +$16.2M +52.6% Dec 31, 2017 10-K 2021-02-25
Q4 2016 $30.7M +$17.4M +131% Dec 31, 2016 10-K 2020-02-25
Q4 2015 $13.3M +$6.84M +106% Dec 31, 2015 10-K 2019-03-18
Q4 2014 $6.44M +$3.55M +122% Dec 31, 2014 10-K 2018-03-12
Q4 2013 $2.9M +$2.21M +320% Dec 31, 2013 10-K 2017-03-15
Q4 2012 $690K Dec 31, 2012 10-K 2016-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.